Hon CHRIS HIPKINS: No, that would be an overly simplistic way of thinking about things. In an international market for vaccines at the moment, one doesn't just simply email out an order and say, "Here's what I want and when I want it." There is some discussion that is required with the suppliers, who at the moment are facing unprecedented international demand and do have a limited capacity to supply. But the series of agreements that we've had with Pfizer have always envisaged that when a paediatric dose was made available or developed, if a paediatric dose was made available, then New Zealand would want to have access to that. 